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Abstract
Background: Although it is well established that prostate cancer (PCa) patients are more likely to experience
clinical depression than their age-matched non-prostate cancer peers, and that such depression can have negative
effects upon survival, little is known about the underlying nature of the depressive symptomatology that these
men experience. In particular, the incidence of melancholic symptoms of depression, which are signs of increased
risk of suicide and resistance to treatment, has not previously been reported in PCa patients. The present study
aimed to measure the incidence and nature of Melancholia in PCa depression.
Method: A sample of 507 PCa patients in Queensland, Australia, completed anonymous and confidential
questionnaires about their background, treatment status, and depression. Data were analysed to select depressive
symptoms that were part of the definition of Melancholia vs those which were not. Regression was used to
determine the links between Melancholia and overall depressive status, and factor analysis revealed the underlying
components of Melancholia, which were mapped over time since diagnosis for 3 years.
Results: Psychometric data were satisfactory. Melancholia significantly predicted depressive status for the most
depressed subset of patients, but not for the total sample. Melancholia was factored into its components of
Anhedonia and Agitation, and the first of these was more powerful in predicting Melancholia. Variability over the 3
years following diagnosis was noted for each of these two components of Melancholia.
Conclusions: The strong presence of Melancholia in the depressive symptomatology of this sample of PCa
patients suggests that some forms of treatment for depression may be more likely to succeed than others. The
dominance of Anhedonia and Agitation over other symptoms of Melancholia also holds implications for treatment
options when assisting these men to cope with their depression.
Background
About 25 percent of prostate cancer (PCa) patients
experience significant depression as a result of their ill-
ness, its diagnosis, or its treatment [1-3]. As well as
emotional distress, depressed PCa patients also have sig-
nificantly greater chances of admission to emergency
treatment, hospitalization, outpatient visits and death
[4]. Therefore, the ongoing investigation of the causes of
depression among PCa patients and the efficacy of inter-
ventions aimed at reducing the intensity of that depres-
sion is clearly justified. Underlying that research is an
understanding of the nature and structure of depression
as it is experienced by this patient group, particularly as
regards one of the major forms of depression—melan-
cholic depression [5], which may have implications for
both assessment and treatment of depression in PCa
patients [6].
Although the first records of the term “melancholia”
date from the ancient Greeks (from melas (meaning
black) and khole (bile)), it was used by Hippocrates
(Aphorisms, section 6.23) to describe what is nowadays
referred to as “general depression": “If a fright or
despondency lasts for a long time, it is a melancholic
affliction”[7], rather than the subset of depressive symp-
toms which are grouped under the modern term “mel-
ancholia”. Melancholia was also used during the Middle
Ages by Avicenna, in his Canon of Medicine,w h o
described it as a depressive mood disorder which was
also called “acedia”, meaning an absence of caring[8],
much like anhedonia in modern definitions of
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p. 32] reported melancholy, its causes, symptoms and
remedies in great detail, describing a typical sufferer as
“we call him melancholy, that is dull, sad, sour, lumpish,
ill-disposed, solitary, any way moved, or displeased”.
Samuel Johnson, in his description of Rasselas, Prince of
Abisinnia [10], referred to “melancholy” as containing a
strong dose of unwarranted guilt, thereby linking the
d i s o r d e rw i t ht h o s ew h ow e r ep r o n et os u p e r s t i t i o n .
During the 18
th century, this focus upon the personality
characteristics of those who suffered from melancholy
was replaced by an emphasis upon more physiological
bases, principally low energy and slowed circulation[11],
and the modern term “depression” was eventually used
in place of melancholia. The latter term was then
adopted to describe a particular subset of depressive
symptoms.
Melancholic patients have been characterised as suf-
fering from extreme and persistent anhedonia, plus psy-
chomotor retardation or agitation, excessive guilt or
hopelessness, suicidal features, and appetite disturbances
or weight changes, all of which distinguish patients with
melancholic depression from those with more general
distress [6,12,13]. Of interest, patients with predomi-
nantly melancholic symptoms are not necessarily more
depressed than others, with at least 50% of people who
score in the upper half of the severity range for depres-
sion not showing the symptoms of melancholia [14].
These behavioural symptoms of melancholia have biolo-
gical substrates that contribute to them, including dys-
function of the hypothalamic-pituitary-adrenal axis
(which influences emotions and the sympathetic nervous
system and may produce guilt and hopelessness [15]),
the thyroid axis (which may contribute to psychomotor
abnormalities, weight loss and sleep disturbances [16]),
rapid eye movement patterns during sleep (which may
be a result of altered circadian rhythms and thus contri-
bute to sleep disturbances [17]), and left dorsolateral
prefrontal cortex activity (which is linked with mood
disorders [18]).
These concomitant biological factors which may occur
before or alongside the psychological symptoms of
depression may be potentially compounded by the phy-
siological symptoms of cancer in general (or its treat-
ment), leading some researchers to opt for the use of
scales which omit somatic symptoms (e.g., the Hospital
Anxiety and Depression Scale). For example, one study
which used the same depression-screening scale as was
used in the present study reported a factor structure for
that scale which broke total scores into cognitive,
depressed mood, and two somatic components among a
sample of 1,109 patients with a range of cancers
(although PCa was not mentioned in the sample
description)[19], suggesting that the “neurovegetative
symptoms of depression were separable from the cogni-
tive/ideational symptoms, with the latter being more
reliable for diagnostic purposes” (p. 126), and that some
somatic symptoms might be attributable to cancer and
its treatment as much as to depression. However,
another study with a mixed cancer sample (5% of the
sample were PCa patients) and which used an abbre-
viated form of the same depression-screening scale
found that this (somatic item-free) abbreviated scale
correlated .91 with the entire (somatic item-inclusive)
scale[20], thus challenging the argument that all somatic
items need to be excluded from assessment of depres-
sion among cancer patients.
While there is some validity in the argument proposed
regarding deletion of somatic items from depression
screening of mixed cancer patients due to the potential
range of cancer-related physiological symptoms which
might be confounded with depression symptomatology,
the specific cancer-related symptoms that have been
reported in PCa patients narrows the range of somatic
symptoms that may need to be excluded. For example,
several major reviews of specific PCa-related symptoms
refer to: incontinence and impotence, problems with
urinary control, sexual and bowel function[21], tumor
flare, hot flashes, and gynecomastia where antiandrogens
are used[22]. Radiation-induced proctitis and bleeding
have also been reported in PCa patients[23]. While
these can cause significant discomfort, and may lead to
some of the behavioural symptoms of melancholia listed
at the commencement of this paragraph, they do not
readily overlap with the somatic symptoms of depression
as defined via the DSM-IV-TR, and it may be that scales
which screen for depression and which include somatic
symptoms can be delivered with some degree of confi-
dence as long as the depression symptoms assessed are
not those reported (above) that arise from PCa itself or
its treatment.
Some data suggest that depressed persons who exhibit
melancholic features are more likely to attempt violent
suicide [24], although that outcome may be more
related to some of the specific symptoms of melancholic
depression such as guilty feelings, anhedonia and loss of
interest rather than the complete group of symptoms
that comprise melancholia [25]. In either case, the
increased likelihood of suicide in PCa patients who exhi-
bit melancholic features of depression lends urgency to
investigations of the presence of melancholia among this
patient group. As an additional impetus to such investi-
gations, there is a longstanding clinical belief that
patients with melancholic depression respond better to
pharmacological treatments than to psychotherapy [26],
presumably because of the powerful biological underpin-
n i n g st ot h e i rd e p r e s s i o n .H o w e v e r ,t h a tp o s i t i o nh a s
been challenged as being more likely related to the
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than the psychological/behavioural symptomatology
itself [17].
Despite the importance of understanding the extent of
melancholia among depressed PCa patients, and how
this might inform choice of treatments for those PCa
patients whose depression exhibits melancholic features,
a search of Google Scholar, PubMed and Science Direct
in August, 2011, using the descriptors “prostate cancer,
melancholic depression”,f a i l e dt oi d e n t i f ya n ys t u d y
which had examined this issue within the PCa popula-
tion. Therefore, the present study was designed to inves-
tigate the incidence of melancholic depression among a
sample of PCa patients (using Frequencies analysis in
SPSS), whether melancholic or nonmelancholic symp-
tom clusters were stronger predictors of overall depres-
sive status (using Linear Regression), whether
melancholic symptomatology was more common or
more intense among PCa patients who had severe
depression than those with less severe depression (via
MANOVA), and also to explore the structure of melan-
cholic depression in a sample of PCa patients (via Factor
Analysis), with a view to informing treatment recom-
mendations for this patient group. Because of the
exploratory nature of this study, a priori power analyses
were not conducted, and post hoc examination of
reported B values was done instead.
Methods
Sample
From 965 PCa patients in Brisbane, Australia, who were
invited by letter to participate, 507 (52.22%) completed
usable questionnaires. All participants had cancers lim-
ited to the primary site and regional draining lymph
nodes using conventional staging investigations. Treat-
ments included radiotherapy, plus hormone therapy and
surgery when required.
Measures
Background questionnaire: age, living situation, month
and year of first diagnosis, treatments received and con-
tinuing, present status of their cancer.
Depression: The Zung Self-Rating Depression Scale
(SDS) [27] is a standardised paper and pencil test of
depression that has been used in studies of depression
in PCa patients [e.g., 28, 29]. Having been developed on
the basis of factor analytic studies of the syndrome of
depression which underlie the DSM definition [5], the
SDS includes items for all of the current DSM-IV-TR
criteria for Major Depressive Episode (MDE). The SDS
has 20 items and respondents are asked to indicate the
frequency of each of the depressive symptoms contained
in those 20 items “during the last two weeks” by
answering in one of four possible ways: “None or a little
of the time”, “Some of the time”, “Good part of the
time”,o r“Most or all of the time”.R a ws c o r e sr a n g e
from 20 to 80, with higher scores being indicative of
more severe depression. The SDS has demonstrated
split-half reliability of .81 [27], .79 [30] and .94 [31].
Internal consistency (alpha) has been reported as .88 for
depressed patients and .93 for non-depressed patients
[32], and as .84 and .83 for previous Australian PCa
samples [28,33]. The SDS has been shown to be super-
ior to the MMPI Depression Scale and the Beck Depres-
sion Inventory for assessing depression in male
psychiatric inpatients [32]. SDS scores of 40 or above
indicate the presence of “clinically significant depres-
sion” [34, p. 335]. SDS raw scores were used in this
study.
Melancholia: There are several scales which measure
certain aspects of Melancholia such as anhedonia (e.g.,
the Chapman Physical and Social Anhedonia Scale [35]
and the Snaith-Hamilton Pleasure Scale [36]), but are
less able to tap other features. In addition to this issue
of validity, there is also a potential measurement con-
found in using separate scales for depression and Mel-
ancholia, because some of the MDE symptomatology
will be emphasised by repetition across two scales, and
thereby alert participants to the relative importance of
these features over non-melancholia features. Similarly,
ethical considerations argue against applying two scales
when one will suffice.
Therefore, because the SDS taps all the symptoms of
MDE, it might also be used to measure the subset of items
which are features of Melancholia. In order to identify
which SDS items were also features of Melancholia, the
first and second authors (both clinical psychologists who
between them had over five decades experience in asses-
sing and diagnosing MDE) allocated each of the 20 SDS
items to the various criteria for melancholic depression as
it is defined in the wider literature (described in the Intro-
duction). That allocation was performed separately and
blindly, and 11 of the SDS items were allocated with 100%
agreement in this way (these 11 items are shown below in
Table 1). The remaining 9 items were agreed to be not
related to Melancholia, thus providing two subsets of SDS
items: those related to melancholia (called “Melancholia”)
and those not related to melancholia ("Nonmelancholia”).
The mean scores on each of these two subsets of SDS
items may be used to clarify the underlying melancholic
nature of the depression experienced by the men in this
study. As for each of the 20 SDS items, the mean scores
for each of these two subsets of SDS items had a range of
possible scores from 1 to 4.
Ethical approval for this study was obtained from the
Wesley Human Research Ethics Committee, Brisbane.
All participants gave written consent to take part in the
study.
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Demographic data
None of the background variables showed any signifi-
cant correlation with SDS scores.
Psychometric data
Reliability (Cronbach’s alpha) was satisfactory for the
SDS (.84), allowing further examination of these data
[37]. The mean SDS score was 34.92/80 (SD = 8.81),
ranging from 20 to 66. The 5% trimmed mean was
34.58, only 0.34 less than the sample mean, thus dis-
counting outlier effects. Skewness, kurtosis, boxplot
inspection and examination of the Normal Q-Q Plot
and Detrended Normal Q-Q Plot argued for the nor-
mality of these SDS data.
Melancholia vs Nonmelancholia
Using the entire sample, the mean score for the Mel-
ancholia subset of SDS items was 1.778/4 (SD = 0.417),
median = 1.700, ranging from 1.00 to 3.40; and the
mean for Nonmelancholia SDS items was 1.721 (SD =
0.508), median = 1.667, ranging from 1.00 to 3.56. Relia-
bility for the Melancholia subset of SDS items was .703,
and skewness was .482, reflecting a slight clustering of
scores to the left of the 1 to 4 point distribution, and
kurtosis was 0.027, almost normal. Reliability for the
Nonmelancholia subset of SDS items was .736, and
skewness was .495, again indicating a slight clustering
left of the mean, and kurtosis was -.335, reflecting a
fairly flat distribution. None of the Q-Q Plots showed
any departure from normality for these data
Using the Wilcoxen Signed Rank test, there was a sig-
nificant difference between the distributions of these
two subsets of SDS items (M Melancholia = 1.777, SD =
.417; M Nonmelancholia = 1.721, SD = .508: z = 13.898,
p < .001), with a small effect size (r =. 1 7 )f o rt h et o t a l
sample. To test if either of the two SDS subsets of items
was a stronger predictor of SDS total score for the total
sample, multiple regression was applied to the sample’s
scores on Melancholia and Nonmelancholia SDS items,
and these were regressed against the total SDS score.
The R square was .985, indicating that (as might be
expected) almost all the variance in the SDS total score
was predicted by these two subsets of SDS items; this
result was significant (F(2,506) = 171.000, p < .001).
Examination of the Beta weights (standardised coeffi-
cients) showed that Nonmelancholia made the strongest
unique contribution to the SDS total score (b = .552, p
< .001), followed by Melancholia (b = .518, p < .001),
although both were significant predictors of the SDS
total score.
Despite previous findings that Melancholia was not
necessarily an indication of severe depression, there was
a significant correlation between scores on the Melanch-
olia subset of SDS items and SDS total score (r = .915, p
< .001), accounting for 83.72% of the variance. There-
fore, to explore this relationship further, Zung’s recom-
mended SDS cutoff score of 40 for “clinically
significant” depression was applied to the entire sample,
and 147 patients were identified as falling into this more
severe depression category. The mean score for the Mel-
ancholia subset of SDS items for this subsample was
2.259/4 (SD = 0.296), median = 2.30, ranging from 1.60
to 3.40; the mean for Nonmelancholia SDS items was
2.314/4 (SD = 0.321), median = 2.333, ranging from
1.67 to 3.56. Using the Wilcoxen Signed Rank test, there
was no significant difference between the distributions
of these two subsets of SDS items (z = 1.594, ns)f o r
this most depressed subsample. Multiple regression was
applied to this subsample’s scores on Melancholia and
Nonmelancholia SDS items. The R square was .934, and
this result was significant (F(2,146) = 1,022.000, p <
.001). Examination of the Beta weights (standardised
coefficients) showed that, in reverse to the finding for
the total sample, Melancholia made the strongest unique
contribution to the SDS total score (b =. 6 3 1 ,p < .001),
followed by Nonmelancholia (b = .576, p < .001),
although (again) both were significant predictors of the
SDS total score.
Finally, to test for the presence of significant differ-
ences between the PCa patients who had “clinically sig-
nificant” depression versus those whose SDS score was
below the recommended cutoff, MANOVA was used to
compare the two subsamples on both Melancholia and
Nonmelancholia subsets of SDS items. There was a sig-
nificant main effect (F(2,504) = 470.00, p < .001, Wilks
Lambda, partial eta squared = .651). Univariate testing
indicated that the more severely depressed subsample
had significantly higher mean scores for Melancholia
(2.259) than the less severely depressed subsample
(1.578: F = 613,145, p < .000); the same was true for
Nonmelancholia (2.314 vs 1.475: F = 669.015, p < .000).
Table 1 SDS Melancholia items and their Beta weights
(Standardised) as predictors of SDS total score
SDS item Beta weight
20. I still enjoy doing the things I used to .262
17. I feel I am useful and needed .220
15. I am more irritable than usual .197
18. My life is pretty full .178
5. I eat as much as I used to .161
13. I am restless and can’t keep still .152
6. I still enjoy sex .145
2. Morning is when I feel best .144
19. I feel others would be better off if I were dead .091
9. My heart beats faster than usual .087
7. I notice that I am losing weight .078
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sents a group of symptoms rather than a single symp-
tom [6,12,13] (thus leading to the choice of SDS items
to form a Melancholia subscale), and therefore the rela-
tive power of each of those symptoms to predict the
total SDS score is of interest, and was investigated via
multiple regression. The R square for the regression
analysis was .889, indicating that a great deal of the var-
iance in the SDS total score was predicted by the 11
SDS items that tapped melancholic features. This result
was significant (F(11, 515) = 366.153, p < .001). The
items and their Beta weights (standardised coefficients)
are presented in descending order of predictive power
in Table 1, and suggest that the first five SDS items
shown in Table 1 (i.e., items 20, 17, 15, 18 and 5), plus
item 6 might reflect anhedonia; items 13 and 9 may
represent agitation; items 2 and 7 are discrete aspects of
melancholia previously reported in the literature; and
item 19 may indicate low self-esteem.
However, those groupings of SDS items with aspects
of melancholia are based upon literal interpretation of
each SDS item’s content. While that is one way of
grouping items for this purpose, another method is to
apply factor analysis to the sample’s responses to these
items and then identify factors. There were many inter-
item correlations greater than .3, the Kaisser-Meyer-
Olkin measure of sampling adequacy was .784 (exceed-
ing the recommended value of 0.6 ) and Bartlett’s test of
sphericity was significant (p < .001), thus justifying fac-
tor analysis with these data. Three components had
eigenvalues greater than 1.0, but analysis of the screeplot
via Catell’s test and parallel analysis revealed that only
the first two of these justified further examination.
Together, these two components accounted for 42.428%
of the variance (Factor 1 = 28.586%, Factor 2 =
13.842%). The component correlation matrix showed
only a small correlation between these two components
(r = .125) (accounting for less than 2% of the variance),
arguing for their discreteness. When forced into a two-
factor solution via Oblimin Rotation, the pattern matrix
showed that SDS items 2, 5, 17, 18, 20 loaded on Factor
1, and SDS items 9, 13,15 and 19 loaded on Factor 2
(SDS 6 and 7 failed to load on either factor). From
Table 1, the content of these items may be seen, and
Factor 1 was labelled as “Anhedonia”, and Factor 2 as
“Agitation”. The agreement between the factor analytic
and content interpretation methods of identifying the
components of the Melancholic subset of SDS items
contributes to the reliability of that result, and justifies
further investigation of these two components of
Melancholia.
Two final analyses were undertaken using these fac-
torial data. Although these analyses were largely
exploratory, they were potentially informative for the
purposes of planning treatments for PCa patients who
exhibit melancholia. First, regression was used to deter-
mine the relative predictive power of each of the two
components of Melancholia (i.e., Anhedonia, Agitation).
The R square was .912, indicating that almost all the
variance in the Melancholia score was predicted by
these two subfactors, and this result was significant (F
(2,510) = 2,624.000, p < .001). The Beta weight (standar-
dised coefficients) for anhedonia was .766 (p < .001),
and for Agitation it was .419 (p < .001), reflecting the
stronger predictive power of the Anhedonia component
for overall Melancholia.
The second analysis was performed to determine the
presence of any variability in Melancholia, Anhedonia
and Agitation over time. The sample was identified
according to time since diagnosis, and classified into 3-
month cohorts, ranging in subsample size from 10 for
cohort 9 (i.e., 25 to 27 months after diagnosis) to 95 for
cohort 2 (4 to 6 months after diagnosis). Although there
were no significant correlations between time since
diagnosis and SDS total score, the variabilities in total
Melancholia scores (i.e., the mean of the 11 SDS items
that comprise the Melancholia subset), the Anhedonia
score (i.e., mean of items 2, 5, 17, 18, 20) and the Agita-
tion score (mean of items 9, 13,15, 19) are shown in Fig-
ure 1(a) and 1(b). From Figure 1(a), it is apparent that
Melancholia scores were relatively stable, although with
a peak during the initial 3 months, and again at between
25 and 27 months after diagnosis. Anhedonia was high-
est immediately after diagnosis, then dropped for 12
months and increased during the period between 15 and
24 months after diagnosis. Agitation was fairly stable
during the first 12 months after diagnosis but then
increased dramatically at 15 months, decreased after
that, and increased again at 27 months after diagnosis.
Because these changes may have been due to current
disease status (i.e., cancer still present, cancer in remis-
sion, cancer re-occurred after previous treatment) for
various 3-monthly cohorts, MANOVA was conducted
using current disease status over the 3-monthly cohorts
as the Independent Variable and Melancholia, Anhedo-
nia and Agitation as the Dependent Variables. There
was no significant main effect (F(6,966) = 1.542, p =
.161, Wilks Lambda, partial eta square = .009), nor any
significant univariate effects. As noted by Stevens [38],
w i t has a m p l es i z eo fo v e r1 0 0 ,“power is not an issue”
(p. 6), and the b for this analysis was .600, also arguing
that this nonsignificant outcome is not a result of a
Type II error and it may be accepted that the lack of
significant effects was not due to some of the sample
having had unsuccessful treatment for their PCa. Figure
1(b) shows the relative distribution of the two Melanch-
olia factors over the period examined, and reflects a
consistent (although only slightly) higher incidence of
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the 36-month period, and (most importantly for inter-
vention planning) different peaks for the two factors of
Melancholia at different times after diagnosis.
Discussion
The allocation of SDS items into subsets to assess Mel-
ancholic and Nonmelancholic aspects of depression
appears to have been accomplished with satisfactory
internal consistency, and psychometric data allowed for
use of these subscales to discuss the further incidence
and distribution of Melancholia in this sample of PCa
patients. Although the mean score for Melancholia was
significantly higher than that for Nonmelancholia for
the entire sample, Nonmelancholia was a stronger pre-
dictor of total SDS scores. There was a similar (but non-
significant) difference in Melancholia and
Nonmelancholia subset scores for those PCa patients
whose SDS scores placed them in the “clinically signifi-
cant” depression category, but Melancholia was a stron-
ger predictor of total SDS score for this more depressed
subsample. Although not consistently reported in the
previous literature (none of which focussed on PCa
patients), higher depression scores were significantly
(and very meaningfully–over 80% of the variance)
related to Melancholia. In addition, the most depressed
patients were also distinguished by their depressive sta-
tus being more a function of Melancholia than was the
case for the less depressed PCa patients. Thus, depres-
sion in PCa patients appears to be closely related to
Melancholia, making this population different to others
in the literature and supporting the further exploration
of the components of Melancholia that was conducted
here.
The divisions of the Melancholia subset of SDS items
to ‘Anhedonia” and “Agitation” by content analysis and
factor analysis produced markedly similar results, thus
arguing that these two subfactors of Melancholia were
robust in this sample, and produced a valuable extra
metric for analysis of the overall Melancholia construct.
Anhedonia had almost twice the predictive power for
Melancholia as did Agitation, thereby reinforcing the
finding reported above that, at least in this sample of
PCa patients, melancholic depression was principally a
function of loss of interest and/or pleasure in activities
and sources in the patients’ lives. That result was for the
entire sample and provides some insight into the
depressive states of these men. As well as being domi-
nated by Melancholia in an overall sense, the key
aspects of depression for these PCa patients were Anhe-
donia and Agitation, rather than the wider set of fea-
tures that commonly describe Melancholia (such as
excessive guilt or hopelessness, suicidal ideation, and
appetite disturbances or weight changes). Of these two
(i.e., anhedonia and agitation), loss of pleasure and/or
interest is the predominant sub-feature. When subdi-
vided according to time since diagnosis, there were
changes in Melancholia and in the overall and relative
incidence of Anhedonia and Agitation. These findings
might be used to inform treatment planning with PCa
patients.
For example, the relatively dominant position of Mel-
ancholia in the depressive profiles of this sample sug-
gests that it might be profitably considered when
developing psychosocial treatment regimes for men with
PCa. If, as has been long believed, melancholic patients
respond most effectively to medication rather than psy-
chotherapy, then consideration of that avenue of ancil-
lary treatment might be part of the overall PCa
treatment protocols for those men who show signs of
depression. This suggestion is reinforced by the finding
that it was the Anhedonia aspect of Melancholia that
was the strongest component, and that some previous
data have indicated that anhedonia responds relatively
poorly to psychotherapy compared to medication.
Although self-help and self-guided treatments for PCa-
linked depression are to be commended, they will be of
ϭ

(a) 
 
(b) 
3-month cohorts 
Mean 
Scores 
3-month cohorts 
Distribution 
of Factors 
Figure 1 Total Melancholia, Factor 1 (Anhedonia) and Factor 2
(Agitation): (a) incidence over 3-month cohorts, and (b)
comparative weighting of Melancholia by Factors 1 and 2 over
3-month cohorts.
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and who are therefore biologically incapable of experien-
cing pleasure, either from behaviourally-induced activ-
ities or within the therapeutic bond of psychotherapy.
The second major finding that can inform treatment
for PCa patients with Melancholic depression is that
shown in Figures 1(a) and 1(b). Those data suggest that
PCa patients exhibit different depressive profiles at dif-
ferent times following their diagnosis, arguing for varia-
bility in treatment protocols also. As reported in a
previous study [39], the “one size fits all” treatment
approach suffers in the face of changing depressive pro-
files during the three years after initial PCa diagnosis,
and may need to be more closely aligned to the kinds of
symptom variability shown in Figure 1. While Figure 1
(a) can inform therapists about the ‘danger’ periods for
Melancholia, Anhedonia and Agitation, Figure 1(b) may
also provide some planning suggestions regarding the
comparative attention to be given to the Anhedonia vs
Agitation aspects of Melancholia in PCa patients.
There are several limitations to this study. First, a
cross-sectional snapshot was used to gather data rather
than a longitudinal design. While the latter may have
been better able to show within-participant changes
over time, there is also a potential reduction in the
validity of self-report data when participants are asked
to repeatedly comment on their psychological well-
being. Second, the sample was from a single radiation
oncology centre in one state in Australia, and generali-
sability to other types of treatment patient groups, dif-
ferent nationalities and cultures is therefore restricted.
However, the size of the sample, and the robustness of
the statistical findings argue for the validity of these
results with this population. Finally, although a Danish
sample of 278 men and 652 women with major depres-
sion showed that significantly more men than women
fulfilled the criteria for melancholic depression[40], as
mentioned in the Introduction to this paper, no pre-
vious reports were found that focussed upon melancho-
lia in PCa patients. The generalisability to PCa patients
of data collected from severely depressed (but non-can-
cer) patients is not easily demonstrated, and therefore
the present study may be seen as making a unique con-
tribution to the literature regarding PCa patient
depression.
Conclusion
Melancholia played a major role in the depressive pro-
files of this sample of PCa patients, and Anhedonia was
the principal subcomponent of that Melancholia. These
findings suggest that PCa patients may have different
depressive profiles to some previously reported non-PCa
samples, and argue for consideration of specific PCa-
related models of depression that incorporate specific
treatment protocols. Most importantly, these data sug-
gest that there is a reasonable proportion of PCa
patients who have major depression (as previously
reported), that there is a strong chance that they will
also be melancholic, and that anhedonia will underlie
their experiences of depression. Treatment options that
favour pharmacological approaches may need to be
given greater consideration for this segment of PCa
patients who are depressed.
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